Brequinar is under clinical development by Clear Creek Bio and currently in Phase II for Coronavirus Disease 2019 (COVID-19). According to GlobalData, Phase II drugs for Coronavirus Disease 2019 (COVID-19) have a 76% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Brequinar’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Brequinar overview
Brequinar is under development for the treatment of coronavirus disease 2019 caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The drug candidate is administered through oral and intravenous route. It acts by targeting dihydroorotate dehydrogenase (DHODH). The drug candidate was under development for the treatment of relapsed and refractory acute myeloid leukemia, T-cell leukemia, T-cell acute lymphoblastic leukaemia (T-ALL), bi-lineal leukemia (BLL), or mixed phenotypic acute leukemia (MPAL), metastatic colorectal cancer, transplant rejection, autoimmune disorders, non-small cell lung cancer, head and neck cancer squamous cell carcinoma and lymphoproliferative disorders.
Clear Creek Bio overview
Clear Creek Bio (Clear Creek) is a biotechnology company that discovers and develops novel therapies to address infectious disease and cancer. The company is headquartered in Cambridge, Massachusetts, the US.
For a complete picture of Brequinar’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
